Navigation Links
Catalyst mystery unlocked
Date:8/18/2008

Different keys are not supposed to fit the same lock, but in biological systems multiple versions of a catalyst all make a reaction go, according to a new study that explains the phenomenon.

Scheduled for online publication in PNAS Early Edition sometime after Aug. 18, the study challenges entrenched ideas about the workings of catalysts.

The study also suggests a method for designing new catalysts.

Catalysts are molecules that speed up chemical reactions without participating in them. Thousands of industrial and biological processes rely on catalysts. In the human body, enzymes catalyze almost every reaction.

"The Holy Grail of enzyme catalysis and the ultimate manifestation of understanding of this process is the ability to design enzymes," said senior author Arieh Warshel, professor of chemistry at USC College.

He listed drug production, environmental chemistry and bioremediation as areas that could be revolutionized by custom-designed enzymes.

In the PNAS study, Warshel described a computational model that both explains a key aspect of catalyst function and suggests a design strategy.

Since the early days of catalyst chemistry, scientists had championed the "lock and key" model, which held that a catalyst worked by exquisitely surrounding and matching the reacting system (the substrate).

Warshel's group has published several papers in support of an alternate theory based on electrical attraction. According to the group, a perfect physical fit between catalyst and substrate is not necessary.

"What really fits is the electrostatic interaction between the enzyme active site to the substrate charges at the so-called transition state, where the bonds are halfway to being broken," Warshel said.

If Warshel is correct, catalyst and substrate would be less like lock and key, and more like two magnets: As long the opposite poles could get close to each other, they would bind.

Warshel's model reproduced new experimental data showing that a natural enzyme and its engineered, structurally different counterpart both have the same catalytic power, despite being very different from each other.

The engineered enzyme, made by co-author Donald Hilvert of ETH in Zurich, Switzerland, displays less distinct folding than the natural enzyme. It also changes shape very rapidly.

Warshel's model shows that the engineered enzyme takes the shape of many keys, with all fitting electrostatically in the same lock. This should offer a new option for enzyme design.


'/>"/>

Contact: Carl Marziali
marziali@usc.edu
213-740-4751
University of Southern California
Source:Eurekalert

Related medicine news :

1. CATalyst Council Forms to Address Feline Health Care
2. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
3. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
4. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
5. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. CATalyst Summit Declared a Success: Its All About the Cat!
8. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
9. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
10. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
11. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) ... ( http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage ... the watch while sharing these events with caregivers in real time. ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and ... flash, and flare from clip to clip with high quality 4K lens flare footage," ... Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Mich. , Dec. 5, 2016  Sharn Anesthesia ... preferred anesthesia sales and distribution partner for Salter Labs.  ... of the Year in recognition of outstanding sales performance. ... devices for respiratory and anesthesia care, including the market ... is also the master distributor of the Parker Flex-Tip® ...
(Date:12/5/2016)... TrainerMD , the first HIPAA compliant software collaboration platform for patients, ... . Styku, a California -based software ... world-class, real-time 3D body scanning and analysis. Together with its other ... and feel their health like never before. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
Breaking Medicine Technology: